$TMO 8-K earnings — Q2 FY26

Adjusted EPS of $6.03 beat consensus of $5.91 by $0.12 (2.0%). Revenue of $11.99B grew 10% YoY (5% organic), exceeding expectations as end-market strength drove broad-based growth. The market may overlook that GAAP operating margin expanded 50bps to 17.4%, signaling underlying operational leverage even as the company absorbed $1B in share buybacks and a microbiology divestiture.

Adjusted EPS of $6.03 beat consensus of $5.91 by $0.12 (2.0%). Revenue of $11.99B grew 10% YoY (5% organic), exceeding expectations as end-market strength drove broad-based growth. The market may overlook that GAAP operating margin expanded 50bps to 17.4%, signaling underlying operational leverage even as the company absorbed $1B in share buybacks and a microbiology divestiture.